The drug is not effective against the BA.2 subvariant of Moronic, the FDA insists.
Because of this claim, the FDA does not want anyone in New England to even try to find relief from monoclonal antibodies.
Why is the FDA butting its nose into the availability of monoclonal antibodies?
GlaxoSmithKline and Vir Biotechnology, the two manufacturers of sotrovimab, say they are planning to challenge the FDA's decision by sending literature showing that higher doses of monoclonal antibodies are, supposedly effective against BA.2.
"We will continue to monitor BA.2 in all U.S. regions and may revise the authorization further to ensure that patients with COVID-19 have effective treatments available," the FDA said in a statement.
Another monoclonal antibody option called REGEN-COV, made by Regeneron and promoted by former President Donald Trump, was also cut off from the FDA's EUA designation for the same reasons.
"The FDA should not be getting involved AT ALL with doctors treating their patients," suggested someone at The Epoch Times.
https://www.naturalnews.com/2022-03-29-fda-orders-doctors-stop-covid-monoclonal-antibodies.html
No comments:
Post a Comment